GLP1R and metabolic dysfunction-associated steatotic liver disease: Our present study demonstrated that LG, a long-acting GLP-1 analog, reduced lipid accumulation in the steatotic L-02 cell model, and could mimic the pathogenic features of NAFLD (known as simple hepatic steatosis) in humans.